肛周瘘管型克罗恩病相关的肛管直肠癌与瘘管癌:系统评价与专家共识
国际TOpClass联盟多学科专家通过系统评价与Delphi共识,针对肛周瘘管型克罗恩病(PFCD)相关的肛管直肠癌与瘘管癌的筛查、风险评估和管理制定6条共识声明;共纳入76篇文献,总体证据质量低;推荐长期(>10年)PFCD患者应被视为肛周癌风险虽小但增加,新发、难治或进展的肛周症状应促使评估瘘管癌。
要点
- 长期(>10年)PFCD患者肛周癌风险虽小但增加,包括肛管鳞状细胞癌和肛管直肠癌。
- 应考虑肛管鳞状细胞癌的危险因素,尤其是人乳头瘤病毒。
- 新发、难治或进展的肛周症状应促使评估瘘管癌;诊断可能需要多种方式,包括麻醉下检查加活检。
核心结论
- 炎症性肠病临床医生应意识到所有PFCD患者存在PFCD相关肛管直肠癌与瘘管癌的风险;TOpClass联盟共识声明为管理这一棘手情况提供指导。
研究设计与样本
- 国际TOpClass联盟多学科专家采用标准方法学进行系统评价,使用Newcastle-Ottawa量表质量评估工具,随后通过Delphi共识方法制定共识声明。
- 共识别561篇文章,110篇符合条件,最终纳入76篇文章;总体证据质量低。
主要发现
- TOpClass联盟就筛查、风险评估和管理PFCD相关肛管直肠癌与瘘管癌的6条结构化声明达成共识。
- 长期(>10年)PFCD患者应被视为肛周癌(包括肛管鳞状细胞癌和肛管直肠癌)风险虽小但增加。
- 应考虑肛管鳞状细胞癌的危险因素,尤其是人乳头瘤病毒。
- 新发、难治或进展的肛周症状应促使评估瘘管癌。
- 对无症状肛周瘘管患者的筛查时机或频率未达成共识;诊断可能需要多种方式,包括麻醉下检查加活检;多学科团队努力被认为是瘘管癌管理的核心。
关键数值与推荐
- 长期(>10年)PFCD患者应被视为肛周癌风险虽小但增加(共识声明)。
- 应考虑肛管鳞状细胞癌的危险因素,尤其是人乳头瘤病毒(共识声明)。
- 新发、难治或进展的肛周症状应促使评估瘘管癌(共识声明)。
- 对无症状肛周瘘管患者的筛查时机或频率未达成共识(共识声明)。
- 诊断可能需要多种方式,包括麻醉下检查加活检(共识声明)。
临床怎么用
- 炎症性肠病临床医生应意识到所有PFCD患者存在PFCD相关肛管直肠癌与瘘管癌的风险。
- TOpClass联盟共识声明为管理PFCD相关肛管直肠癌与瘘管癌提供指导。
局限性
- 总体证据质量低。
- 对无症状肛周瘘管患者的筛查时机或频率未达成共识。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Perianal fistulizing Crohn's disease (PFCD)-associated anorectal and fistula cancers are rare but often devastating diagnoses. However, given the low incidence and consequent lack of data and clinical trials in the field, there is little to no guidance on screening and management of these cancers. To inform clinical practice, we developed consensus guidelines on PFCD-associated anorectal and fistula cancers by multidisciplinary experts from the international TOpClass consortium. METHODS: We conducted a systematic review by standard methodology, using the Newcastle-Ottawa Scale quality assessment tool. We subsequently developed consensus statements using a Delphi consensus approach. RESULTS: Of 561 articles identified, 110 were eligible, and 76 articles were included. The overall quality of evidence was low. The TOpClass consortium reached consensus on 6 structured statements addressing screening, risk assessment, and management of PFCD-associated anorectal and fistula cancers. Patients with long-standing (>10 years) PFCD should be considered at small but increased risk of developing perianal cancer, including squamous cell carcinoma of the anus and anorectal carcinoma. Risk factors for squamous cell carcinoma of the anus, notably human papilloma virus, should be considered. New, refractory, or progressive perianal symptoms should prompt evaluation for fistula cancer. There was no consensus on timing or frequency of screening in patients with asymptomatic perianal fistula. Multiple modalities may be required for diagnosis, including an examination under anesthesia with biopsy. Multidisciplinary team efforts were deemed central to the management of fistula cancers. CONCLUSIONS: Inflammatory bowel disease clinicians should be aware of the risk of PFCD-associated anorectal and fistula cancers in all patients with PFCD. The TOpClass consortium consensus statements outlined herein offer guidance in managing this challenging scenario.
引用
- Wong SY, Rowan C, Brockmans ED, et al. Perianal Fistulizing Crohn's Disease-Associated Anorectal and Fistula Cancers: Systematic Review and Expert Consensus. Clin Gastroenterol Hepatol. 2024. PMID: 38871152. doi:10.1016/j.cgh.2024.05.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。